Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
- Published In:
- Diabetes, obesity & metabolism, 27(4), 1773-1782 (2025)
- Authors:
- le Roux, Carel W(18), Steen, Oren, Lucas, Kathryn J, Startseva, Elena, Unseld, Anna, Hussain, Samina Ajaz, Hennige, Anita M
- Database ID:
- RPEP-12001
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12001APA
le Roux, Carel W; Steen, Oren; Lucas, Kathryn J; Startseva, Elena; Unseld, Anna; Hussain, Samina Ajaz; Hennige, Anita M. (2025). Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.. Diabetes, obesity & metabolism, 27(4), 1773-1782. https://doi.org/10.1111/dom.16167
MLA
le Roux, Carel W, et al. "Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.." Diabetes, 2025. https://doi.org/10.1111/dom.16167
RethinkPeptides
RethinkPeptides Research Database. "Subgroup analysis by sex and baseline BMI in people with a B..." RPEP-12001. Retrieved from https://rethinkpeptides.com/research/le-2025-subgroup-analysis-by-sex
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.